AbbVie prices Rinvoq close to Humira after arthritis approvalAbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price Share XAbbVie prices Rinvoq close to Humira after arthritis approvalhttps://pharmaphorum.com/news/abbvie-prices-upadacitinib-close-to-humira-after-arthritis-approval/
Mycenax’s Actemra biosimilar edges closer to approvalMycenax’s biosimilar of Roche’s Actemra (tocilizumab), LusiNEX, has been shown to match its originator’s profile in a phase Share XMycenax’s Actemra biosimilar edges closer to approvalhttps://pharmaphorum.com/news/mycenaxs-actemra-biosimilar-edges-closer-to-approval/
RA pill setback spoils Lilly’s growth storyEli Lilly has posted a strong 8% increase in sales for the second quarter, led by growth of Share XRA pill setback spoils Lilly’s growth storyhttps://pharmaphorum.com/news/ra-pill-setback-spoils-lillys-growth-story/
AbbVie looks beyond Humira as RA pill meets phase 3 targetsUpadacitinib hopes drug will reduce reliance on Humira. Share XAbbVie looks beyond Humira as RA pill meets phase 3 targetshttps://pharmaphorum.com/news/abbvie-looks-beyond-humira-ra-pill-meets-phase-3-targets/